A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel |
| |
| Affiliation: | 1. School of Pharmacy, Second Military Medical University, Shanghai, PR China;2. Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian, PR China;3. Shanghai Institute of Pharmaceutical Industry, Shanghai, PR China;4. Tasly Pharmaceutical Group Co., Ltd, Tianjin, PR China;1. Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan;2. Department of pharmaceutics, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt;3. Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy;4. Head of International Publication and Nanotechnology Consultation Center INCC, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Egypt;5. Department of Pharmaceutics Faculty of Pharmacy, Alexandria University, Egypt;1. Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK;2. Department of Mechanical Engineering, University College London, Torrington Place, London, UK;3. School of Clinical Dentistry, University of Sheffield, Claremont Crescent, Sheffield, UK;1. Women''s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA 22003, USA;2. Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, MD, USA;3. Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Fairfax, VA, USA;4. Department of Radiation Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA;5. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA |
| |
| Abstract: | A novel polyethylene glycol 400 (PEG400) mediated lipid nanoemulsion as drug-delivery carrier for paclitaxel (PTX) was successfully developed. The formulation comprised a PEG400 solution of the drug (25 mg/mL) that would be mixed with commercially 20% lipid emulsion to form PTX-loaded nanoemulsion (1 mg/mL) prior to use. This two-vial formulation of PTX-loaded lipid nanoemulsion (TPLE) could significantly reduce extraction of reticuloendothelial system (RES) organs and increase tumor uptake, and exhibited more potent antitumor efficacy on bearing A2780 or Bcap-37 tumor nude mice compared to conventional PTX-loaded lipid nanoemulsion (CPLE). TPLE did not cause haematolysis and intravenous irritation response yet, and showed the same cytotoxicity against HeLa cells as Taxol®, and its LD50 was 2.7-fold higher than that of Taxol®, suggesting its good safety and druggability. In addition, TPLE displayed distinctly faster release of PTX, a greater proportion of PTX in phospholipids layer and a smaller share in oil phase than CPLE. From the Clinical Editor: This study demonstrates the feasibility and potential advantage of a novel PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in clinical application for the cancer therapy.From the Clinical EditorThis team of investigators convincingly demonstrates the feasibility and potential advantage of a PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in cancer therapy, documenting superior safety and faster release of PTX compared to commercially available formulations. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
